OBJECTIVES:Elevated homocysteine levels are considered to be an independent risk factor for cardiovascular complications in diabetic patients. The aim of this study was to find out if zinc supplementation improves homocysteine levels, which may exert vascular-protective effects in type 2 diabetes subjects with microalbuminuria. METHODS: In a randomized, double-blind, controlled, crossover study, 50 type 2 diabetic patients with microalbuminuria were subdivided into two groups and supplemented with 30 mg/d of zinc (group 1) or placebo (group 2) for three months with a four-week wash out period. Serum creatinine, vitamin B(12), folate, fastingplasma glucose, HbA1c, lipid profiles, zinc, homocysteine levels and random urine albumin were measured before and after the first and second phase of the study in all participants. RESULTS:Mean serum zinc was significantly increased after zinc supplementation (from 76 +/- 16 mug/dl to 93 +/- 20 microg/dl; p < 0.05), while there was no change in the placebo group (75 +/- 16 microg/dl to 75 +/- 15 microg/dl). With zinc supplementation, homocysteine levels reduced significantly (from 13.71 +/- 3.84 mumol/l to 11.79 +/- 3.06 mumol/l; p < 0.05), which did not occur on placebo (from 12.59 +/- 2.13 mumol/l to 13.36 +/- 2.03 mumol/l). Simple regression was used to show a positive correlation between urine albumin excretion and serum homocysteine (r = 0.37, p = 0.023). Vitamin B(12) and folate levels increased significantly in patients who received zinc in comparison to those who received placebo. A negative correlation was observed between homocysteine and vitamin B(12) concentration (r = -0.36, p = 0.025). CONCLUSION:Zinc supplementation reduced serum homocysteine and increased vitamin B(12) and folate concentrations in type 2 diabetic patients with microalbuminuria.
RCT Entities:
OBJECTIVES: Elevated homocysteine levels are considered to be an independent risk factor for cardiovascular complications in diabeticpatients. The aim of this study was to find out if zinc supplementation improves homocysteine levels, which may exert vascular-protective effects in type 2 diabetes subjects with microalbuminuria. METHODS: In a randomized, double-blind, controlled, crossover study, 50 type 2 diabeticpatients with microalbuminuria were subdivided into two groups and supplemented with 30 mg/d of zinc (group 1) or placebo (group 2) for three months with a four-week wash out period. Serum creatinine, vitamin B(12), folate, fasting plasma glucose, HbA1c, lipid profiles, zinc, homocysteine levels and random urine albumin were measured before and after the first and second phase of the study in all participants. RESULTS: Mean serum zinc was significantly increased after zinc supplementation (from 76 +/- 16 mug/dl to 93 +/- 20 microg/dl; p < 0.05), while there was no change in the placebo group (75 +/- 16 microg/dl to 75 +/- 15 microg/dl). With zinc supplementation, homocysteine levels reduced significantly (from 13.71 +/- 3.84 mumol/l to 11.79 +/- 3.06 mumol/l; p < 0.05), which did not occur on placebo (from 12.59 +/- 2.13 mumol/l to 13.36 +/- 2.03 mumol/l). Simple regression was used to show a positive correlation between urine albumin excretion and serum homocysteine (r = 0.37, p = 0.023). Vitamin B(12) and folate levels increased significantly in patients who received zinc in comparison to those who received placebo. A negative correlation was observed between homocysteine and vitamin B(12) concentration (r = -0.36, p = 0.025). CONCLUSION: Zinc supplementation reduced serum homocysteine and increased vitamin B(12) and folate concentrations in type 2 diabeticpatients with microalbuminuria.
Authors: A Jager; P J Kostense; G Nijpels; J M Dekker; R J Heine; L M Bouter; A J Donker; C D Stehouwer Journal: Arterioscler Thromb Vasc Biol Date: 2001-01 Impact factor: 8.311
Authors: E K Hoogeveen; P J Kostense; C Jakobs; J M Dekker; G Nijpels; R J Heine; L M Bouter; C D Stehouwer Journal: Circulation Date: 2000-04-04 Impact factor: 29.690
Authors: J B Meigs; P F Jacques; J Selhub; D E Singer; D M Nathan; N Rifai; R B D'Agostino; P W Wilson Journal: Diabetes Care Date: 2001-08 Impact factor: 19.112
Authors: A G Bostom; F Kronenberg; P F Jacques; E Kuen; E Ritz; P König; G Kraatz; K Lhotta; J F Mann; G A Müller; U Neyer; W Riegel; V Schwenger; P Riegler; J Selhub Journal: Atherosclerosis Date: 2001-11 Impact factor: 5.162
Authors: R Jayawardena; P Ranasinghe; P Galappatthy; Rldk Malkanthi; Gr Constantine; P Katulanda Journal: Diabetol Metab Syndr Date: 2012-04-19 Impact factor: 3.320